1Wisniewski T, Coni F. Immunotherapeutic Approaches for Alzheimer's Disease. Neuron, 2015, 85(6): 1162-1176.
2Hyman BT, Marzloff K, Arriagada PV. The lack of accumulation of senile plaques or amyloid burden in Alzheimer' s disease suggests a dynamic balance between amyloid deposition and resolution.J Neuropathol Exp Neurol, 1993, 52 ( 6) : 594-600.
3PriceJL, McKeel DW, Buckles VD, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging, 2009, 30 ( 7 ) : 1026-1036.
4UlrichJ. Abundant neurofibrillary tangles without senile plaques in a subset of patients with senile dementia. Neurodegeneration, 1992, 1: 257-264.
5Arriagada PV , GrowdonJH, Hedley - Whyte ET, et al. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer' s disease. Neurology, 1992, 42 (3):631-639.
6Holmes C, Boche D, Wilkinson D, et al. Long - term effects of A 13 42 immunisation in Alzheimer' s disease: follow - up of a randomised, placebo - controlled phase I trial. Lancet, 2008,372(9634): 216-223.
7Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild - to - moderate Alzheimer' s disease. N EnglJ Med, 2014, 370(4): 322-333.
8Roberts GW, Gentleman SM, Lynch A, et al. 13 amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer's disease.J Neurol Neurosurg Psychiatry, 1994, 57 (4) : 419 -425.
9Regland B, Gottfries CG. The role of amyloid 13 - protein in Alzheimer's disease. Lancet, 1992, 340 (8817) : 467- 469.
10Lopez - Toledano MA, Shelanski ML. Neurogenic effect of 13- amyloid peptide in the development of neural stem cells.J Neurosci, 2004, 24 (23) : 5439 -5444.
